Aardvark Initiates PWS Treatment Trial, Anticipates Q3 2026 Data Readout
Written by Emily J. Thompson, Senior Investment Analyst
Source: Newsfilter
Updated: 22 hour ago0mins
- Trial Initiation: Aardvark Therapeutics has successfully dosed the first patient in Australia for its Phase 3 HERO trial targeting Prader-Willi syndrome, marking a critical advancement in treatment options for this condition, which could significantly impact patient care.
- International Expansion: Regulatory clearance has been obtained for clinical trial sites in Canada and the UK, with enrollment expected to begin shortly, which not only enhances the trial's international scope but also accelerates data collection and analysis.
- High Patient Engagement: All patients who have completed the HERO trial to date have enrolled in the Open Label Extension trial, indicating strong interest in the new therapy, which will help bolster the company's reputation and trust within the patient community.
- Data Release Timeline: Aardvark anticipates topline data to be available in Q3 2026, and maintaining this timeline will position the company favorably in the competitive biopharmaceutical landscape.
AARD.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on AARD
Wall Street analysts forecast AARD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AARD is 30.63 USD with a low forecast of 18.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.980
Low
18.00
Averages
30.63
High
50.00
Current: 13.980
Low
18.00
Averages
30.63
High
50.00
BTIG
initiated
$26
2025-11-07
Reason
BTIG
Price Target
$26
2025-11-07
initiated
Reason
BTIG initiated coverage of Aardvark Therapeutics with a Buy rating and $26 price target. Aardvark is a clinical stage biopharmaceutical company developing ARD-101, a TAS2R agonist for Prader Willi syndrome, and ARD-201 for weight loss and weight rebound prevention, the analyst tells investors in a research note. The firm believes ARD-101's "excellent" safety profile and "differentiated" mechanism are underappreciated by the Street. The real share upside, however, comes from ARD-201 and the opportunity to prevent weight regain from GLP-1 discontinuations, contends BTIG.
JonesResearch
NULL -> Buy
initiated
$33
2025-10-01
Reason
JonesResearch
Price Target
$33
2025-10-01
initiated
NULL -> Buy
Reason
JonesResearch initiated coverage of Aardvark Therapeutics with a Buy rating and $33 price target. Aardvark is a clinical-stage biotech company focused on treating obesity and hyperphagia, the analyst tells investors in a research note. The firm says the company is "gearing up for a transformative year" with two major datasets in the second half of 2026.
Stifel
initiated
$24
2025-09-29
Reason
Stifel
Price Target
$24
2025-09-29
initiated
Reason
Stifel initiated coverage of Aardvark Therapeutics with a Buy rating and $24 price target. The firm believes the company's ARD-101 is an "under-the-radar," late-stage Prader-Willi syndrome play. Stifel believes the drug has a higher probability of sucess than the shares currently imply, creating a "compelling setup." At a $200M enterprise value, Aardvark's risk/reward is "heavily upside-biased," the analyst tells investors in a research note.
RBC Capital
Outperform
maintain
$20 -> $19
2025-08-14
Reason
RBC Capital
Price Target
$20 -> $19
2025-08-14
maintain
Outperform
Reason
RBC Capital lowered the firm's price target on Aardvark Therapeutics to $19 from $20 and keeps an Outperform rating on the shares after its Q2 results. The quarter contained a few timeline slippages as the go-forward clinical plans take clearer shape, most notably the highly-anticipated Prader-Willi phase 3 for '101 now expected in Q3 of 2026 vs. early-2026 previously, though incorporation of pediatric patients in that study may help increase potential effect size and probability of success, the analyst tells investors in a research note.
See All Ratings
About AARD
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What is the significance of Aardvark's Phase 3 HERO trial for PWS?
How does the Open Label Extension trial enhance patient trust in Aardvark?
What are the chances of Aardvark meeting its Q3 2026 data timeline?
How might international trial sites impact the speed of data collection?